Canadian Adverse Reaction Newsletter Volume 12 · Issue 3 · July 2002
In this Issue
Pure red cell aplasia and Eprex
Glitazones: update on adverse reactions
Safety of human insulins
Case presentation - Kava
Summary of advisories
Pure red cell aplasia: suspected
association with epoetin alfa (Eprex)
Eprex, a recombinant human erythropoietin (rHuEPO), is indicated for
"the treatment of anaemia associated with chronic renal failure (CRF),
cancer or concomitantly administered cancer chemotherapy, zidovudine-treated/HIV-infected
patients, for use in patients undergoing autologous donation, and to reduce
allogenic blood exposure for patients undergoing elective surgery."(1)
The "primary adverse effect of erythropoietin has been an excessive increase
in the hematocrit following over-treatment with the hormone in patients
undergoing hemodialysis, leading to the aggravation of hypertension or
thrombotic complications."(2) Recently, however,
pure red-cell aplasia (PRCA), a selective failure of the erythroid elements
in bone marrow resulting in a normochromic, normocytic anemia, has been
reported to be associated with the use of rHuEPO.(3-5)
On Nov. 26, 2001, following discussion with Health Canada, the sponsor
issued a Dear Healthcare Professional Letter informing physicians of the
occurrence of PRCA associated with the use of Eprex. (6)
Since then, there has been a marked increase in the number of PRCA cases
reported to Health Canada: 21 of the 28 cases reported as of Apr. 10,
2002, were received after the letter was issued.
The mechanism underlying PRCA is not well understood. Autoantibodies
against erythropoietin have been shown to inhibit the formation of erythroid
colonies by normal bone marrow cells.(5) PRCA
has been demonstrated to be induced by drugs and chemicals (e.g., phenytoin,
chlorpropamide). (2,5,7)
It has also been associated with a variety of conditions including thymomas,
lymphoproliferative disorders and viral infections such as hepatitis B
and parvovirus infection.(2,7)
Although rare, PRCA can occur during the course of renal failure.(2,7)
The anemia in patients with rHuEPO-induced PRCA is much more severe than
the anemia in patients with renal failure that prompted the rHuEPO therapy.(2)
In addition, most patients with rHuEPO-induced PRCA become permanently
transfusion dependent and may be resistant to other rHuEPO products. (2,5,6)
Health Canada is closely monitoring the issue and has requested that
the manufacturer conduct, and submit the results of, further investigations
to determine the factors that may have contributed to the increased number
of PRCA cases in Canada. More data from ongoing investigations are still
required to assess the risks associated with rHuEPO use. Until then, patients
receiving rHuEPO should be advised to promptly report to their physician
any symptoms associated with worsening anemia (e.g., excessive fatigue,
pallor, syncope). Physicians should consult the product monograph for
hematology monitoring requirements. Health professionals are encouraged
to continue to report to Health Canada any suspected or confirmed cases
of PRCA in patients using rHuEPO.
Xuguang Li, MD, Ph.D; Supriya Sharma, MD, MPH, FRCPC, Health Canada
References
1. Eprex, sterile solution
[product monograph]. Toronto: Janssen-Ortho Inc; 2001 Jan 26.
2. Bunn HF. Drug-induced
autoimmune red-cell aplasia. N Engl J Med 2002;346(7):522-3.
3. Peces R, de la Torre
M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin
in a patient with erythropoietin-resistant anemia. N Engl J Med 1996;335(7):523-4.
4. Prabhakar SS, Muhlfelder
T. Antibodies to recombinant human erythropoietin causing pure red cell
aplasia. Clin Nephrol 1997;47(5):331-5.
5. Casadevall N, Nataf J,
Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell
aplasia and antierythropoietin antibodies in patients treated with recombinant
erythropoietin. N Engl J Med 2002;346(7):469-75.
6. Important new safety
information -- Eprex (epoetin alfa): reports of pure red blood cell anemia
[Dear Healthcare Professional Letter]. Toronto: Janssen-Ortho Inc., Ortho
Biotech; 2001 Nov 26. Available: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2001/eprex_hpc-cps_e.html
(accessed 2002 May 24).
7. Croisille L, Tchernia
G, Casadevall N. Autoimmune disorders of erythropoiesis. Curr Opin
Hematol 2001;8(2):68-73.
Rosiglitazone (Avandia) and pioglitazone
(Actos): update on cardiovascular and hepatic adverse reactions
Rosiglitazone (Avandia) and pioglitazone (Actos), members of the thiazolidinedione
oral antidiabetic class of drugs, were marketed in Canada in March and
August 2000, respectively. In Canada, Avandia is indicated for use as
an adjunct to diet and exercise as monotherapy or in combination with
metformin or a sulfonylurea in patients with type 2 diabetes mellitus.
1 Actos is indicated as monotherapy for
type 2 diabetes not controlled by diet and exercise.2
Health Canada continues to monitor cardiac disorders and hepatic reactions
with these drugs. Table 1 summarizes
reports of suspected adverse reactions (ARs) associated with rosiglitazone
and pioglitazone received since the date they were marketed in Canada
to Mar. 1, 2002. Spontaneous reporting systems are suitable to detect
signals of potential drug safety issues; however, quantitative comparisons
of drug safety cannot be made from these data.
Table 1: Reports submitted
to Health Canada of suspected adverse reactions (ARs) associated with
thiazolidinediones from date marketed in Canada to Mar. 1, 2002*
Thirty-six of the 282 reports received for rosiglitazone and 4 of the
29 received for pioglitazone were of heart failure or congestive heart
failure. Cases of edema were also reported without heart failure.
Ten of the 282 suspected AR reports received for rosiglitazone indicated
a fatal outcome; 3 of these were described in the July 2001 issue of the
newsletter.3 Three of the remaining 7 suspected
fatal cases reported heart failure or congestive heart failure, with 2
of these also indicating myocardial infarction. The other 4 fatal cases
involved pulmonary edema (1), enlarged abdomen and peripheral edema (1),
bone marrow depression with concomitant use of Imuran (1) and a complex
case of a serum-sickness-type reaction and erythema multiforme (1), which
occurred shortly after the rosiglitazone was started and which resulted
in multiple organ failure. There was 1 report of a fatal outcome associated
with pioglitazone in which the patient had a cardiorespiratory arrest,
was found to have elevated liver enzymes and died of anoxic encephalopathy.
The patient had no history of liver disease but had a history of extensive
alcohol consumption and was taking other drugs. Causality assessment is
difficult in most of these cases because of the lack of information or
the complexity of the cases.
People with type 2 diabetes are at increased risk of diabetes-related
complications such as congestive heart failure. However, results of an
observational study based on analysis of insurance claims indicated that
the use of glitazones was associated with a significant increase in risk
of heart failure in diabetic patients treated with glitazones compared
with diabetic patients who did not use glitazones. 4
However, these results were published as an abstract only, and further
research is needed to confirm these findings.
To minimize the risk of hepatic and cardiovascular adverse events, physicians
are advised to adhere to all recommendations and monitoring guidance listed
in the product monograph. The product monographs of Avandia1
and Actos2 list the following as contraindications:
- known hypersensitivity to the product or any of its components;
- serious hepatic impairment; and
- acute heart failure.
Health Canada has been continuously monitoring the safety profile of
the glitazones. The following actions have been taken to inform health
care professionals and the public regarding safety issues with these products:
· At product launch in Canada, Dear Healthcare Professional
Letters were issued by the manufacturers of Avandia5
and Actos6 recommending that precautions
be taken and that patients be monitored for liver and cardiac adverse
reactions.
· A summary of hepatic, cardiac and hematological reactions
with rosiglitazone was presented in the July 2001 issue of the newsletter.3
· In consultation with Health Canada a second Dear Healthcare
Professional Letter was issued by the manufacturer of Actos (on Nov. 6,
20017) and by the manufacturer of Avandia
(on Nov. 13, 20018) regarding new safety
information related to fluid retention and congestive heart failure.
· Health Canada issued a public Advisory on the safety
profile of the thiazolidinediones on Nov. 29, 2001,9
related to fluid retention and congestive heart failure.
Your continued reporting of suspected ARs associated with the use of
the glitazones is an important factor in evaluating their safety in the
postmarketing phase.
Duc Vu, MSc, Ph.D; Mano Murty, MD, CCFP, FCFP; Marielle McMorran, BScPharm,
Health Canada
References
1. Avandia, rosiglitazone
maleate tablets [product monograph]. Mississauga (ON): GlaxoSmithKline
Inc; 2001 Oct 19.
2. Actos, pioglitazone
hydrochloride tablets [product monograph]. Toronto (ON): Eli Lilly
Canada Inc; 2001 Nov 19 / Oct 26.
3. McMorran M, Vu D. Rosiglitazone
(Avandia): hepatic, cardiac and hematological reactions. Can Adverse
Drug Reaction Newsl 2001;11(3):2-3. Also in CMAJ 2001;165(1):82-3.
4. Delea T, Hagiwara M,
Edelsberg J, Oster G. Exposure to glitazone antidiabetics and risk of
heart failure among persons with type 2 diabetes: a retrospective population-based
cohort analysis [abstract]. J Am Coll Cardiol 2002;39(5 Suppl A):858.
5. Avandia [Dear
Healthcare Professional Letter]. Oakville (ON): SmithKline Beecham Pharma;
March 2000.
6. Actos [Dear
Healthcare Professional Letter]. Toronto: Eli Lilly Canada Inc; Sept 2000.
7. Important safety
information regarding Actos [Dear Healthcare Professional Letter].
Toronto: Eli Lilly Canada Inc; 2001 Nov 6. Available: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2001/actos_hpc-cps_e.html
(accessed 2002 May 28).
8. Important safety
information regarding Avandia [Dear Healthcare Professional Letter].
Mississauga (ON): GlaxoSmithKline Inc; 2001 Nov 13. Available:
http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2001/avandia_hpc-cps_e.html
(accessed 2002 May 28).
9. Important safety reminder
for patients taking oral diabetes drugs of the glitazone class, Avandia®
and Actos® [Public Advisory]. Ottawa: Health Canada; 2001 Nov
29. Available: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2001/2001_132_e.html
"It's Your Health": The Safety of
Human Insulins
In the previous 2 years attention has been focused, in media reports
and elsewhere, on concerns regarding the safety of recombinant human insulin
and the availability of animal insulin in Canada. In an effort to clarify
these issues Health Canada has posted an "It's Your Health" document on
its Web site (http://www.hc-sc.gc.ca/iyh-vsv/med/insul_e.html),
with a link to it from the Canadian Diabetes Association's update on human
and animal insulins (http://ww.diabetes.ca/Section_About/bromley.asp).
A distribution by fax to targeted health professionals and special interest
groups was also done.
The document briefly outlines the background of the manufacture and sale
of recombinant human and animal insulins in Canada, and their availability.
In addition, it addresses the benefits of human insulins, how Health Canada
monitors the adverse effects of insulin, and the effects of switching
insulins, stressing that the choice of insulin for an individual should
be made after discussion with the treating physician.
From 1983 to Mar. 31, 2002, Health Canada received about 550 reports
of suspected ARs associated with recombinant human insulins. Of these
suspected AR reports, 9 indicated a fatal outcome. From 1965, when Health
Canada started monitoring ARs, until Mar. 31, 2002, about 250 reports
of ARs associated with animal insulins were received, 20 of which were
of a fatal outcome. Quantitative safety comparisons of these products
cannot be made on the basis of spontaneous AR reports because patient
exposure is unknown and underreporting exists.
Recombinant human insulins have an established safety profile, with over
200 000 Canadians using them daily to manage their diabetes. If one assumes
that patients have 2 injections a day on average, about 146 million doses
are administered per year. Considering the high numbers of users, the
complexity of diabetes as a disease and the benefits obtained with the
use of human insulins, the number of reports of suspected ARs is not believed
to suggest any unusual trend in the safety profile of these products.
Regulators in other international jurisdictions have confirmed similar
findings.
Supriya Sharma MD, MPH, FRCPC, Health Canada
Case Presentation - Kava
As a result of the Public Advisory concerning kava and liver toxicity
issued by Health Canada on Jan. 16, 2002, 3 case reports of suspected
hepatic adverse reactions were received. One of these cases involved a
53-year-old woman who took 3 to 10 capsules of kava (dosage unspecified)
daily over a 2-year period. She also took St. John's wort, vitamins and
other herbs for depression and anxiety. Four years earlier the patient
had developed an inflamed liver because of alcohol consumption but had
stopped drinking in the last 2 years. Three weeks before medical consultation,
the patient experienced fatigue, vomiting, loss of weight, jaundice and
darker urine. At presentation she had an enlarged liver and elevated bilirubin,
aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase
levels. After the patient stopped taking the kava, her liver profile returned
to normal and her symptoms resolved.
Summary of health professional and consumer
advisories
issued since Feb. 15, 2002
Date |
Product |
Subject and Web address |
May 23 |
Celebrex
(celecoxib) |
Important safety information for patients taking CELEBREX® (celecoxib)
- consumer information
|
May 16 |
Longdan |
Warning not to consume Longdan and Lung Tan Xie Gan
Products - consumer information |
May 16 |
Plas+SD |
Important safety information: PLAS+SD plasma (human)
- Precision Pharma Services Inc. |
May 14 |
Rapamune
(sirolimus) |
Important correction to drug safety information on
Rapamune |
May 13 |
Celebrex
(celecoxib) |
Important drug safety information on Celebrex |
May 2002 |
Insulins |
It's Your Health: The safety of human insulins - consumer
information |
Apr. 29 |
HIV
test kits |
Health Canada advises Canadians about potential false
results with certain rapid HIV test kits - consumer information |
Apr. 19 |
Vioxx
(rofecoxib) |
Important safety information for patients taking VIOXX®
(rofecoxib) - consumer information |
Apr. 15 |
Vioxx
(rofecoxib) |
Important drug safety information on VIOXX® - Merck
Frosst Canada Inc. |
Apr. 12 |
IGIV
(Immune Globulin) |
Thrombotic events and immune globulin intravenous (IGIV)
- Baxter |
Apr. 11 |
Tutoplast Dura |
Important medical devices safety advisory - Tutoplast
Dura manufactured by Tutogen Medical GmbH |
Apr. 5 |
Hua
Fo |
Health Canada warns public not to use Hua Fo (DIN 02243366)
- consumer information |
Apr. 4 |
Phosphate
Solutions |
Important safety information for patients taking sodium
phosphates oral solutions (Fleet® Phospho-soda® and Phosphates Solution)
- consumer information |
Mar. 27 |
Meridia
(sibutramine) |
Health Canada investigates safety of MERIDIA® (sibutramine)
- consumer information |
Mar. 22 |
Non-sterile medical devices |
Non-sterile medical devices labeled as sterile manufactured
by A & A Medical, Rocket USA and LifeQuest |
Mar. 18 |
Sodium Phosphates
Oral Solutions |
Important safety information regarding Phosphates Solution
(Sodium Phosphates Oral Solution DIN 02230399) - Pharmascience Inc. |
Mar. 15 |
Sodium Phosphates
Oral Solutions |
Important safety information regarding Fleet® Phospho-Soda®
(Sodium Phosphates Oral Solution) - Johnson & Johnson · Merck |
Mar. 6 |
Zerit
(stavudine, d4T) |
Symptoms mimicking the clinical presentation of Guillain-Barré
syndrome associated with ZERIT® (stavudine, d4T) - Bristol-Myers Squibb |
To receive the Newsletter and health product Advisories
free by email,
join Health Canada's MedEffect e-Notice mailing list.
Go to http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/index_e.html
and click on "subscribe".
|